Abstract
APOE-ε4 is the strongest genetic risk factor for Alzheimer’s disease (AD), and is associated with an increase in the levels of amyloid deposition and an early age of onset. Recent data demonstrate that AD pathological changes occur decades before clinical symptoms, raising questions about the precise onset of the disease. Now a convergence of approaches in mice and humans has demonstrated that APOE-ε4 affects normal brain function even very early in life in the absence of gross AD pathological changes. Normal mice expressing APOE4 have task-specific spatial learning deficits, as well as reduced NMDAR-dependent signaling and structural changes to presynaptic and postsynaptic compartments in neurons, particularly in hippocampal regions. Young humans possessing APOE-ε4 are more adept than APOE-ε4 negative individuals at some behavioral tasks, and functional magnetic resonance imaging has shown that inheritance of APOE-ε4 has specific effects on medial temporal brain activities. These findings suggest that inheritance of APOE-ε4 causes life long changes to the brain that may be related to the late risk of AD. Several possible mechanisms of how APOE-ε4 could affect brain neurochemistry, structure, and function are reviewed.
Keywords: Apolippoprotein E, amyloid, entorhinal cortex, dendritic spine, hippocampus, targeted replacement mice, prevention, risk factor.
Current Alzheimer Research
Title:Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function
Volume: 13 Issue: 11
Author(s): Amanda M. Di Battista, Nicolette M. Heinsinger and G. William Rebeck
Affiliation:
Keywords: Apolippoprotein E, amyloid, entorhinal cortex, dendritic spine, hippocampus, targeted replacement mice, prevention, risk factor.
Abstract: APOE-ε4 is the strongest genetic risk factor for Alzheimer’s disease (AD), and is associated with an increase in the levels of amyloid deposition and an early age of onset. Recent data demonstrate that AD pathological changes occur decades before clinical symptoms, raising questions about the precise onset of the disease. Now a convergence of approaches in mice and humans has demonstrated that APOE-ε4 affects normal brain function even very early in life in the absence of gross AD pathological changes. Normal mice expressing APOE4 have task-specific spatial learning deficits, as well as reduced NMDAR-dependent signaling and structural changes to presynaptic and postsynaptic compartments in neurons, particularly in hippocampal regions. Young humans possessing APOE-ε4 are more adept than APOE-ε4 negative individuals at some behavioral tasks, and functional magnetic resonance imaging has shown that inheritance of APOE-ε4 has specific effects on medial temporal brain activities. These findings suggest that inheritance of APOE-ε4 causes life long changes to the brain that may be related to the late risk of AD. Several possible mechanisms of how APOE-ε4 could affect brain neurochemistry, structure, and function are reviewed.
Export Options
About this article
Cite this article as:
Battista M. Di Amanda, Heinsinger M. Nicolette and Rebeck William G., Alzheimer’s Disease Genetic Risk Factor APOE-ε4 Also Affects Normal Brain Function, Current Alzheimer Research 2016; 13 (11) . https://dx.doi.org/10.2174/1567205013666160401115127
DOI https://dx.doi.org/10.2174/1567205013666160401115127 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Neurodegenerative Diseases: A Review of Upstream and Downstream Antioxidant Therapeutic Options
Current Neuropharmacology The Association of Folic Acid Deficiency and Diabetic Nephropathy in Patients with Type 2 Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Molecular Mechanisms of Skeletal Muscle Insulin Resistance in Type 2 Diabetes
Current Diabetes Reviews Receptor-Binding and Pharmacokinetic Properties of Dopaminergic Agonists
Current Topics in Medicinal Chemistry Translational Applications of Tissue Engineering in Cardiovascular Medicine
Current Pharmaceutical Design Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension
Current Vascular Pharmacology Meet the Editorial Board
Current Vascular Pharmacology Improvement in Hypertension Management with Pharmacological and Non- Pharmacological Approaches: Current Perspectives
Current Pharmaceutical Design Structure of Atherosclerotic Plaques in Different Vascular Territories: Clinical Relevance
Current Vascular Pharmacology Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design The Effects of Prostaglandin E-1 in Patients with Intermittent Claudication
Cardiovascular & Hematological Disorders-Drug Targets Statins And Stroke
Current Medicinal Chemistry Transdermal Delivery of Captopril and Metoprolol Tartrate with Microneedles
Drug Delivery Letters Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Mediterranean Diet and Oxidation: Nuts and Olive Oil as Important Sources of Fat and Antioxidants
Current Topics in Medicinal Chemistry Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Inflammation, Sleep, Obesity and Cardiovascular Disease.
Current Vascular Pharmacology Drug-Drug Interactions Associated with Antiplatelet Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Oral IIa and Xa Inhibitors for Prevention of Stroke in Atrial Fibrillation: Clinical Studies and Regulatory Considerations
Current Clinical Pharmacology